Optimization and evaluation of astragalus polysaccharide injectable thermoresponsive in-situ gels.

The objective of this study was to develop an injectable in situ forming gel system based on Poloxamer for sustained release of Astragalus polysaccharide (APS), thus achieved once or twice administration instead of frequent dosing during long-term treatment. The optimal formulation is 10 g APS, 18 g...

Full description

Bibliographic Details
Main Authors: Zugong Yu, Fanxi Guo, Yangyang Guo, Zhenrui Zhang, Feng Wu, Xiaoqing Luo
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2017-01-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC5369758?pdf=render
id doaj-9a00c16451874add9dec5071c220fc8a
record_format Article
spelling doaj-9a00c16451874add9dec5071c220fc8a2020-11-25T02:47:26ZengPublic Library of Science (PLoS)PLoS ONE1932-62032017-01-01123e017394910.1371/journal.pone.0173949Optimization and evaluation of astragalus polysaccharide injectable thermoresponsive in-situ gels.Zugong YuFanxi GuoYangyang GuoZhenrui ZhangFeng WuXiaoqing LuoThe objective of this study was to develop an injectable in situ forming gel system based on Poloxamer for sustained release of Astragalus polysaccharide (APS), thus achieved once or twice administration instead of frequent dosing during long-term treatment. The optimal formulation is 10 g APS, 18 g poloxamer 407, 2 g poloxamer 188, 0.15 g CMC-Na, 0.85 g sodium chloride in 100 ml gel in situ which had a preferable sol-gel transition temperature(T sol-gel) (34.1 ± 0.4°C), and good stability. In vitro release studies, all formulations containing polymer additives had prolonged release time and decreased initial burst to some extent. The optimal formulation containing 0.15% CMC-Na showed a best sustained release profile for about 132 h with the lowest initial burst in vitro about 16.30% in 12 h). In vivo, Male BALB/c mice (18-20 g) were administrated with APS in-situ gel just once, the values of immune organ indices, spleen lymphocyte proliferation, and serum IgM, IgG, IL-2 and IL-6 had significant increase, which was consistent with the mice given daily APS injections (7 times), while the above indices were increased more significantly in which administrated with APS in-situ gel twice. Based on these results, it can be concluded that the Poloxamer depot is a promising carrier for the sustained release of APS with an ideal release behavior.http://europepmc.org/articles/PMC5369758?pdf=render
collection DOAJ
language English
format Article
sources DOAJ
author Zugong Yu
Fanxi Guo
Yangyang Guo
Zhenrui Zhang
Feng Wu
Xiaoqing Luo
spellingShingle Zugong Yu
Fanxi Guo
Yangyang Guo
Zhenrui Zhang
Feng Wu
Xiaoqing Luo
Optimization and evaluation of astragalus polysaccharide injectable thermoresponsive in-situ gels.
PLoS ONE
author_facet Zugong Yu
Fanxi Guo
Yangyang Guo
Zhenrui Zhang
Feng Wu
Xiaoqing Luo
author_sort Zugong Yu
title Optimization and evaluation of astragalus polysaccharide injectable thermoresponsive in-situ gels.
title_short Optimization and evaluation of astragalus polysaccharide injectable thermoresponsive in-situ gels.
title_full Optimization and evaluation of astragalus polysaccharide injectable thermoresponsive in-situ gels.
title_fullStr Optimization and evaluation of astragalus polysaccharide injectable thermoresponsive in-situ gels.
title_full_unstemmed Optimization and evaluation of astragalus polysaccharide injectable thermoresponsive in-situ gels.
title_sort optimization and evaluation of astragalus polysaccharide injectable thermoresponsive in-situ gels.
publisher Public Library of Science (PLoS)
series PLoS ONE
issn 1932-6203
publishDate 2017-01-01
description The objective of this study was to develop an injectable in situ forming gel system based on Poloxamer for sustained release of Astragalus polysaccharide (APS), thus achieved once or twice administration instead of frequent dosing during long-term treatment. The optimal formulation is 10 g APS, 18 g poloxamer 407, 2 g poloxamer 188, 0.15 g CMC-Na, 0.85 g sodium chloride in 100 ml gel in situ which had a preferable sol-gel transition temperature(T sol-gel) (34.1 ± 0.4°C), and good stability. In vitro release studies, all formulations containing polymer additives had prolonged release time and decreased initial burst to some extent. The optimal formulation containing 0.15% CMC-Na showed a best sustained release profile for about 132 h with the lowest initial burst in vitro about 16.30% in 12 h). In vivo, Male BALB/c mice (18-20 g) were administrated with APS in-situ gel just once, the values of immune organ indices, spleen lymphocyte proliferation, and serum IgM, IgG, IL-2 and IL-6 had significant increase, which was consistent with the mice given daily APS injections (7 times), while the above indices were increased more significantly in which administrated with APS in-situ gel twice. Based on these results, it can be concluded that the Poloxamer depot is a promising carrier for the sustained release of APS with an ideal release behavior.
url http://europepmc.org/articles/PMC5369758?pdf=render
work_keys_str_mv AT zugongyu optimizationandevaluationofastragaluspolysaccharideinjectablethermoresponsiveinsitugels
AT fanxiguo optimizationandevaluationofastragaluspolysaccharideinjectablethermoresponsiveinsitugels
AT yangyangguo optimizationandevaluationofastragaluspolysaccharideinjectablethermoresponsiveinsitugels
AT zhenruizhang optimizationandevaluationofastragaluspolysaccharideinjectablethermoresponsiveinsitugels
AT fengwu optimizationandevaluationofastragaluspolysaccharideinjectablethermoresponsiveinsitugels
AT xiaoqingluo optimizationandevaluationofastragaluspolysaccharideinjectablethermoresponsiveinsitugels
_version_ 1724753484553650176